Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The stock was acquired at an average price of $15.34 per share, for a total transaction of $153,400.00. Following the acquisition, the director now owns 106,062 shares in the company, valued at approximately $1,626,991.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NYSE:VRX opened at $15.44 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 4.25. Valeant Pharmaceuticals International Inc has a 52-week low of $8.31 and a 52-week high of $24.43. The firm has a market capitalization of $5,508.19, a PE ratio of 4.03, a P/E/G ratio of 0.33 and a beta of -0.32.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals International had a return on equity of 42.48% and a net margin of 27.56%. The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.18 billion. During the same period in the prior year, the business earned $1.26 earnings per share. The business’s revenue was down 10.0% on a year-over-year basis. equities analysts anticipate that Valeant Pharmaceuticals International Inc will post 3.12 EPS for the current fiscal year.
A number of research analysts have recently issued reports on the company. Zacks Investment Research upgraded Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Mizuho upgraded Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $10.00 to $15.00 in a report on Friday. Wells Fargo reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, March 20th. ValuEngine downgraded Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, Deutsche Bank set a $20.00 target price on Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Wednesday, March 21st. Five equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $18.56.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.